A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
77actual
Sites
25
Countries
Australia, Canada, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-07 | actual | When the study began enrolling |
| Primary completion | 2026-07-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: AMG 355
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Who Experience a Dose Limiting Toxicity (DLT)
measured Day 1 to Day 21
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
measured Up to 2 years
Number of Participants Who Experience a Treatment-related AE
measured Up to 2 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed